<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04758234</url>
  </required_header>
  <id_info>
    <org_study_id>18082</org_study_id>
    <secondary_id>J3H-MC-GZNA</secondary_id>
    <nct_id>NCT04758234</nct_id>
  </id_info>
  <brief_title>A Study of LY3549492 in Healthy Participants</brief_title>
  <official_title>A Randomized, Double-Blind, Single-Ascending Dose and Multiple-Dose, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3549492 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the safety and tolerability of LY3549492 in&#xD;
      healthy participants. The blood tests will be performed to check how much LY3549492 gets into&#xD;
      the bloodstream and how the body handles LY3549492. This study includes two parts and will&#xD;
      last up to approximately 76 days for each participant, including screening.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 22, 2021</start_date>
  <completion_date type="Anticipated">January 3, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 3, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline through final follow-up at approximately Day 76</time_frame>
    <description>A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3549492</measure>
    <time_frame>Predose up to 48 days postdose</time_frame>
    <description>PK: AUC of LY3549492</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Maximum Concentration (Cmax) of LY3549492</measure>
    <time_frame>Predose up to 48 days postdose</time_frame>
    <description>PK: Cmax of LY3549492</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LY3549492 (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3549492 administered orally as single ascending doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3549492 (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3549492 administered orally as multiple ascending doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3549492</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>LY3549492 (Part A)</arm_group_label>
    <arm_group_label>LY3549492 (Part B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy Males and females (excluding women of childbearing potential at the time of&#xD;
             signing the informed consent)&#xD;
&#xD;
          -  Glycated hemoglobin (HbA1c) value of &lt;6.5% at screening&#xD;
&#xD;
          -  Body mass index (BMI) within the range 20 to 40 kilograms per square meter (kg/m²),&#xD;
             inclusive&#xD;
&#xD;
          -  Capable of giving signed informed consent form (ICF)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have obesity induced by endocrine disorders such as Cushing's syndrome or Prader-Willi&#xD;
             syndrome.&#xD;
&#xD;
          -  Have significant history of or current cardiovascular, respiratory, hepatic, renal,&#xD;
             Gastro-intestine (GI) (including cholecystectomy with no sequelae, GI disease that&#xD;
             significantly impact gastric emptying or motility, such as severe gastroparesis or&#xD;
             pyloric stenosis even if treated), endocrine, hematological, psychiatric or&#xD;
             neurological disorders capable of significantly altering the absorption, metabolism,&#xD;
             or elimination of drugs; of constituting a risk when taking the study medication; or&#xD;
             of interfering with the interpretation of data.&#xD;
&#xD;
          -  Have undergone any form of bariatric surgery.&#xD;
&#xD;
          -  Have a history or presence of pancreatitis (history of chronic pancreatitis or&#xD;
             idiopathic acute pancreatitis), elevation in serum amylase or lipase (&gt;2.5 fold the&#xD;
             upper limit of normal (ULN)).&#xD;
&#xD;
          -  Have a personal or family history of medullary thyroid carcinoma or have Multiple&#xD;
             Endocrine Neoplasia Syndrome Type 2.&#xD;
&#xD;
          -  Have a serum calcitonin level of ≥20 nanogram/liter (ng/L) at screening, if estimated&#xD;
             glomerular filtration rate is ≥60 milliliter/minute/1.73 square meter (mL/min/1.73&#xD;
             m2).&#xD;
&#xD;
          -  Have an active or history of malignancy within 5 years prior to screening, except for&#xD;
             basal cell or squamous epithelial carcinomas of the skin or in situ carcinoma of the&#xD;
             uterine cervix that have been resected with no evidence or recurrence or metastatic&#xD;
             disease for at least 3 years.&#xD;
&#xD;
          -  Have known liver disease, obvious clinical signs, or symptoms of liver disease, acute&#xD;
             or chronic hepatitis, or have elevations in aminotransferases (alanine&#xD;
             aminotransferase [ALT] and aspartate aminotransferase [AST]) greater than 2 times&#xD;
             [ULN]).&#xD;
&#xD;
          -  Have total bilirubin level (TBL) &gt;1.5 × ULN (except for participants diagnosed with&#xD;
             Gilbert's syndrome).&#xD;
&#xD;
          -  Have serum triglyceride &gt;500 milligram/deciliter (mg/dL) at screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@Lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Covance Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>469-513-6727</phone>
    </contact>
    <investigator>
      <last_name>Jeanelle Kam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 16, 2021</study_first_submitted>
  <study_first_submitted_qc>February 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2021</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

